Dr. Alberto Chiappori, MD

Internal Medicine Tampa, FL Male
NPI: 1952331654
Total Payments
$617,120
2024 Payments
$147.06
Companies
33
Transactions
587
Medicare Patients
756
Medicare Billing
$139,261

Payment Breakdown by Category

Other$427,018 (69.2%)
Consulting$95,509 (15.5%)
Travel$69,612 (11.3%)
Research$12,585 (2.0%)
Food & Beverage$12,220 (2.0%)
Education$174.93 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $412,495 128 66.8%
Consulting Fee $95,509 41 15.5%
Travel and Lodging $69,612 227 11.3%
Honoraria $14,524 12 2.4%
Unspecified $12,585 4 2.0%
Food and Beverage $12,220 172 2.0%
Education $174.93 3 0.0%

Payments by Type

General
$604,535
583 transactions
Research
$12,585
4 transactions

Top Paying Companies

Company Total Records Latest Year
Takeda Pharmaceuticals U.S.A., Inc. $193,826 146 $0 (2022)
Genentech USA, Inc. $99,007 91 $0 (2022)
Millennium Pharmaceuticals, Inc. $79,667 75 $0 (2017)
Merck Sharp & Dohme LLC $54,524 54 $0 (2022)
Celgene Corporation $22,703 20 $0 (2019)
Amgen Inc. $22,256 16 $0 (2023)
AstraZeneca Pharmaceuticals LP $22,254 40 $0 (2021)
PFIZER INC. $16,029 19 $0 (2022)
Novartis Pharmaceuticals Corporation $15,021 11 $0 (2020)
Blueprint Medicines Corporation $14,841 17 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $147.06 1 JAZZ PHARMACEUTICALS INC. ($147.06)
2023 $15,227 10 Amgen Inc. ($4,802)
2022 $77,025 53 Takeda Pharmaceuticals U.S.A., Inc. ($58,131)
2021 $47,702 39 Blueprint Medicines Corporation ($10,188)
2020 $32,640 22 Takeda Pharmaceuticals U.S.A., Inc. ($7,655)
2019 $131,294 134 Takeda Pharmaceuticals U.S.A., Inc. ($39,511)
2018 $127,703 132 Takeda Pharmaceuticals U.S.A., Inc. ($78,635)
2017 $185,383 196 Millennium Pharmaceuticals, Inc. ($79,667)

All Payment Transactions

587 individual payment records from CMS Open Payments — Page 1 of 24

Date Company Product Nature Form Amount Type
05/31/2024 JAZZ PHARMACEUTICALS INC. ZEPZELCA (Drug) Food and Beverage In-kind items and services $147.06 General
Category: HEMATOLOGY/ONCOLOGY
12/01/2023 Mirati Therapeutics, Inc. KRAZATI (Drug) Consulting Fee Cash or cash equivalent $1,837.50 General
Category: ONCOLOGY
11/30/2023 Daiichi Sankyo Inc. — Consulting Fee Cash or cash equivalent $1,250.00 General
11/30/2023 Daiichi Sankyo Inc. — Consulting Fee Cash or cash equivalent $625.00 General
10/23/2023 Amgen Inc. LUMAKRAS (Drug) Consulting Fee Cash or cash equivalent $4,802.00 General
Category: Oncology
10/20/2023 Mirati Therapeutics, Inc. KRAZATI (Drug) Consulting Fee Cash or cash equivalent $1,837.50 General
Category: ONCOLOGY
06/02/2023 Coherus Biosciences Inc. Udenyca (Biological) Consulting Fee Cash or cash equivalent $129.85 General
Category: Granulocyte colony stimulating factor
06/01/2023 Jazz Pharmaceuticals Inc. — Food and Beverage In-kind items and services $94.87 General
03/30/2023 AbbVie Inc. — Consulting Fee Cash or cash equivalent $4,400.00 General
03/01/2023 Mirati Therapeutics, Inc. KRAZATI (Drug) Food and Beverage Cash or cash equivalent $124.95 General
Category: ONCOLOGY
02/22/2023 Lilly USA, LLC RETEVMO (Drug) Food and Beverage Cash or cash equivalent $124.95 General
Category: Oncology
12/15/2022 Takeda Pharmaceuticals U.S.A., Inc. EXKIVITY (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $7,650.00 General
Category: ONCOLOGY
12/06/2022 Takeda Pharmaceuticals U.S.A., Inc. EXKIVITY (Drug) Travel and Lodging In-kind items and services $1,279.95 General
Category: ONCOLOGY
12/01/2022 Takeda Pharmaceuticals U.S.A., Inc. EXKIVITY (Drug) Travel and Lodging In-kind items and services $132.25 General
Category: ONCOLOGY
11/30/2022 Takeda Pharmaceuticals U.S.A., Inc. EXKIVITY (Drug) Food and Beverage In-kind items and services $124.99 General
Category: ONCOLOGY
11/30/2022 Takeda Pharmaceuticals U.S.A., Inc. EXKIVITY (Drug) Travel and Lodging In-kind items and services $48.00 General
Category: ONCOLOGY
11/30/2022 Takeda Pharmaceuticals U.S.A., Inc. EXKIVITY (Drug) Food and Beverage In-kind items and services $13.86 General
Category: ONCOLOGY
11/28/2022 Takeda Pharmaceuticals U.S.A., Inc. ALUNBRIG (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,530.00 General
Category: ONCOLOGY
11/11/2022 Amgen Inc. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $433.00 General
10/29/2022 Pharmacyclics LLC, an AbbVie Company — Food and Beverage In-kind items and services $33.53 General
10/27/2022 Takeda Pharmaceuticals U.S.A., Inc. ALUNBRIG (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $7,650.00 General
Category: ONCOLOGY
10/27/2022 Takeda Pharmaceuticals U.S.A., Inc. EXKIVITY (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,530.00 General
Category: ONCOLOGY
10/15/2022 Takeda Pharmaceuticals U.S.A., Inc. ALUNBRIG (Drug) Travel and Lodging In-kind items and services $461.02 General
Category: ONCOLOGY
10/15/2022 Takeda Pharmaceuticals U.S.A., Inc. ALUNBRIG (Drug) Travel and Lodging In-kind items and services $388.80 General
Category: ONCOLOGY
09/29/2022 Takeda Pharmaceuticals U.S.A., Inc. ALUNBRIG (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $7,650.00 General
Category: ONCOLOGY
123…24»

Research Studies & Clinical Trials

Study Name Company Amount Records
RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy Ipsen Bioscience Inc $4,750 1
RESILIENT A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection ONIVYDE Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy Ipsen Bioscience Inc $4,500 1
NIROGACESTAT CLINICAL PUBLICATION PROGRAM PFIZER INC. $3,200 1
RESEARCH RELATED PUBLICATION SUPPORT Novartis Pharmaceuticals Corporation $134.82 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 3 179 300 $78,380 $35,223
2022 3 195 333 $81,004 $38,470
2021 3 228 347 $83,475 $42,593
2020 3 154 264 $56,882 $22,975
Total Patients
756
Total Services
1,244
Medicare Billing
$139,261
Procedure Codes
12

All Medicare Procedures & Services

12 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 94 214 $51,239 $23,848 46.5%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 72 72 $24,676 $10,327 41.9%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 13 14 $2,465 $1,048 42.5%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 98 233 $52,821 $26,267 49.7%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 71 71 $23,283 $10,162 43.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 26 29 $4,900 $2,042 41.7%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 106 221 $47,685 $26,042 54.6%
99205 New patient outpatient visit, total time 60-74 minutes Facility 2021 96 96 $31,200 $14,182 45.5%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 26 30 $4,590 $2,369 51.6%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 72 155 $33,325 $13,717 41.2%
99205 New patient office or other outpatient visit, typically 60 minutes Facility 2020 40 40 $13,000 $5,318 40.9%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 42 69 $10,557 $3,940 37.3%

About Dr. Alberto Chiappori, MD

Dr. Alberto Chiappori, MD is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952331654.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alberto Chiappori, MD has received a total of $617,120 in payments from pharmaceutical and medical device companies, with $147.06 received in 2024. These payments were reported across 587 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($412,495).

As a Medicare-enrolled provider, Chiappori has provided services to 756 Medicare beneficiaries, totaling 1,244 services with total Medicare billing of $139,261. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.

Practice Information

  • Specialty Internal Medicine
  • Other Specialties Medical Oncology
  • Location Tampa, FL
  • Active Since 07/05/2006
  • Last Updated 12/28/2007
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • NPI Number 1952331654

Products in Payments

  • ALUNBRIG (Drug) $249,142
  • KEYTRUDA (Biological) $50,074
  • TECENTRIQ (Biological) $47,939
  • Alecensa (Biological) $23,668
  • EXKIVITY (Drug) $22,890
  • Abraxane (Drug) $22,703
  • IMFINZI (Drug) $21,793
  • Avastin (Biological) $16,757
  • LUMAKRAS (Drug) $15,420
  • GAVRETO (Drug) $13,416
  • ZEPZELCA (Drug) $11,395
  • OPDIVO (Biological) $10,886
  • ONIVYDE (Drug) $9,250
  • ROZLYTREK (Biological) $8,097
  • ZYKADIA (Drug) $7,856
  • GILOTRIF (Drug) $7,284
  • MEKINIST (Drug) $6,904
  • brigatinib (Drug) $5,346
  • XALKORI (Drug) $4,130
  • KRAZATI (Drug) $3,800

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in Tampa

Javier Pinilla-Ibarz, Md, MD

Internal Medicine — Payments: $1.9M

Internal Medicine $1.9M

Ricardo Restrepo-Jaramillo, M.d, M.D

Internal Medicine — Payments: $562,511

Internal Medicine $562,511

Dr. Sady Alpizar, Md, MD

Internal Medicine — Payments: $509,824

Internal Medicine $509,824

Jhanelle Gray, Md, MD

Internal Medicine — Payments: $273,892

Internal Medicine $273,892

Dr. Andrew Kuykendall, M.d, M.D

Internal Medicine — Payments: $273,357

Internal Medicine $273,357

Mayer Fishman, Md, MD

Internal Medicine — Payments: $270,522

Internal Medicine $270,522